OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kreitman on Results of Moxetumomab Pasudotox in Hairy Cell Leukemia

June 28th 2018

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the findings of moxetumomab pasudotox as a treatment for patients with relapsed/refractory hairy cell leukemia.

Dr. Bekaii-Saab on the ReDOS Study in Metastatic Colorectal Cancer

June 27th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the ReDOS study of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Dr. Schwark on Microsatellite Instability and Lynch Syndrome

June 27th 2018

Alicia Latham Schwark, MD, medical genetics fellow, Memorial Sloan Kettering Cancer Center, discusses a study exploring microsatellite instability (MSI) and how it relates to Lynch syndrome across all tumor types. The findings were presented at the 2018 ASCO Annual Meeting.

Dr. Postow on the FDA Approval of Encorafenib and Binimetinib in BRAF-Mutant Melanoma

June 27th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of encorafenib plus binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Dr. Pennell on the Economic Impact of Next-Generation Sequencing

June 27th 2018

Nathan Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the economic impact of next-generation sequencing.

Dr. McCann on Ongoing Research in HER2-Positive Breast Cancer

June 27th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses ongoing research in the field of HER2-positive breast cancer.

Dr. Gerber on Advances in Radiation Oncology in Breast Cancer

June 27th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses advances in radiation oncology in the treatment of patients with breast cancer.

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC

June 27th 2018

Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.

Dr. Kwa on the Potential Impact of Biosimilars in Oncology

June 27th 2018

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the potential impact of biosimilars in oncology.

Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer

June 27th 2018

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer

June 27th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Dr. Katzel on Women Being Undertreated for Head and Neck Cancer

June 27th 2018

Jed Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses research presented at the 2018 ASCO Annual Meeting, which evaluated whether women are undertreated for head and neck cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Dr. Hong on Advances in Head and Neck Cancer

June 25th 2018

Waun K. Hong, MD, FACP, DMSc, division head, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and 2018 Giant of Cancer Care® in Head and Neck Cancer, discusses advances in the treatment of patients with head and neck cancer.

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

June 25th 2018

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Dr. Raje Discusses the Tolerability of bb2121 in Myeloma

June 25th 2018

Noopur Raje, MD, director Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the tolerability of bb2121 as a treatment for patients with multiple myeloma.

Dr. Mato Discusses a Phase II Trial of Umbralisib in CLL

June 25th 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC

June 23rd 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the combination of avelumab (Bavencio) plus lorlatinib in patients with non–small cell lung cancer.

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

June 23rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the rationale for the IMvigor130 study in metastatic bladder cancer.